Neutralising antibody escape of SARS‐CoV‐2 spike protein: risk assessment for antibody‐based Covid‐19 therapeutics and vaccines
The Spike protein is the target of both antibody‐based therapeutics (convalescent plasma,
polyclonal serum, monoclonal antibodies) and vaccines. Mutations in Spike could affect …
polyclonal serum, monoclonal antibodies) and vaccines. Mutations in Spike could affect …
Convalescent plasma therapy for COVID-19: state of the art
Convalescent plasma (CP) therapy has been used since the early 1900s to treat emerging
infectious diseases; its efficacy was later associated with the evidence that polyclonal …
infectious diseases; its efficacy was later associated with the evidence that polyclonal …
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
Protective effects of lactoferrin against SARS-CoV-2 infection in vitro
C Salaris, M Scarpa, M Elli, A Bertolini, S Guglielmetti… - Nutrients, 2021 - mdpi.com
SARS-CoV-2 is a newly emerging virus that currently lacks curative treatments. Lactoferrin
(LF) is a naturally occurring non-toxic glycoprotein with broad-spectrum antiviral …
(LF) is a naturally occurring non-toxic glycoprotein with broad-spectrum antiviral …
Cardiac injury associated with severe disease or ICU admission and death in hospitalized patients with COVID-19: a meta-analysis and systematic review
X Li, X Pan, Y Li, N An, Y Xing, F Yang, L Tian, J Sun… - Critical care, 2020 - Springer
Background Cardiac injury is now a common complication of coronavirus disease (COVID-
19), but it remains unclear whether cardiac injury-related biomarkers can be independent …
19), but it remains unclear whether cardiac injury-related biomarkers can be independent …
COVID-19–associated coagulopathy and inflammatory response: what do we know already and what are the knowledge gaps?
K Goerlinger, D Dirkmann, A Gandhi… - Anesthesia & …, 2020 - journals.lww.com
Patients with coronavirus disease 2019 (COVID-19) frequently experience a coagulopathy
associated with a high incidence of thrombotic events leading to poor outcomes. Here …
associated with a high incidence of thrombotic events leading to poor outcomes. Here …
[HTML][HTML] Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?
AM Darwesh, W Bassiouni, DK Sosnowski… - Pharmacology & …, 2021 - Elsevier
Abstract Coronavirus disease 2019 (COVID-19), caused by the Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2), has currently led to a global pandemic with …
Syndrome Coronavirus 2 (SARS-CoV-2), has currently led to a global pandemic with …
Cytokine storm syndrome in SARS-CoV-2 infections: a functional role of mast cells
Cytokine storm syndrome is a cascade of escalated immune responses disposing the
immune system to exhaustion, which might ultimately result in organ failure and fatal …
immune system to exhaustion, which might ultimately result in organ failure and fatal …
Kinases as potential therapeutic targets for anti-coronaviral therapy
T Pillaiyar, S Laufer - Journal of Medicinal Chemistry, 2021 - ACS Publications
The global coronavirus disease-19 (COVID-19) has affected more than 140 million and
killed more than 3 million people worldwide as of April 20, 2021. The novel human severe …
killed more than 3 million people worldwide as of April 20, 2021. The novel human severe …
[HTML][HTML] Acute pancreatitis and COVID-19: A literature review
BACKGROUND Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
responsible for the ongoing pandemic of coronavirus disease 2019 (COVID-19), and has …
responsible for the ongoing pandemic of coronavirus disease 2019 (COVID-19), and has …